Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023.
Against a backdrop of manufacturing prioritisation, Novo ... pen needles market. The needle device market is forecast to grow to over $6.8bn by 2033, according to analysis by GlobalData. Novo ...
Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback